Clinical trial · Observational
Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia
Study of the Level of Mannose Binding Lectin (MBL) as a Predictor of the Onset of a Invasive Fungal Infection (IFI) During Chemo-induced Aplasia in Patients With Acute Leukemia (AL)
NCT02823132CI-TRIAL-00022876MBL INFFONGcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate levels of a protein, mannose binding lectin, in patients with acute leukemia who develop or not an invasive fungal infection.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| Invasive Fungal Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- patients who develop a fungal infection
- interventionNames
- Biological: blood sample
- label
- patients without fungal infection
- interventionNames
- Biological: blood sample
Primary outcomes (1)
- measure
- serum level of Mannose Binding Lectin (MBL) in patients with acute leukemia
- timeFrame
- 1st day of the period of aplasia
Secondary outcomes (1)
- measure
- Serum levels of MBL during an episode of aplasia for both groups of patients studied
- timeFrame
- Every day except Saturday and Sunday for roughly 3 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria : * persons who have provided written consent * Patients with national health insurance cover * Patients with malignant hemopathy who have been treated with chemotherapy able to induce profound neutropenia (PN \< 500 / mm3) lasting more than 10 days. * Patients with malignant hemopathy who have received an autologous bone marrow graft * Patients with severe idiopathic medullar aplasia (PN \< 500 / mm3) who need to be hospitalized for at least 10 consecutive days (with or without treatment with immunosuppressants) Exclusion Criteria: * Patients who have received an bone marrow PSC allograft (as such patients have a risk of aspergillosis, which appears in most cases after medullar recovery; they will not be included in the study). * Patients who have received an autologous PSC graf (as the duration of neutropenia is in most cases less than 10 days). * Patients whose neutropenia, retrospectively assessed, lasted less than 10 days.
References
Publications (0)
Data not yet available
No reference posted for this study.